Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a life sciences manufacturer with a strong presence in the protein sciences and diagnostics and genomics segments, with a significant portion of its revenue coming from the United States and other global markets. The company has a solid track record of successful regulatory processes and its recent acquisition by Merck KGaA is not expected to face any major antitrust issues. Although there are some potential risks to consider, such as acquisition and cell therapy progress, Bio-Techne's strong position in the biotech market and its strategic initiatives make it well positioned to benefit from the expected rebound in demand and potential future growth opportunities.

Bears say

Bio-Techne is a global company with a strong presence in the life sciences market, but operational challenges and risks, such as potential share loss and reliance on cell therapy development, make its stock a risky investment. Additionally, the company's mixed track record with acquisitions adds uncertainty. While Bio-Techne continues to find opportunities for self-improvement, its growth may be slow to rebound, and current regulatory conditions suggest a sector performance for the future.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.